Novo Nordisk Pharmatech

Activities: Ingredients Research & Development

Trending Articles

  1. NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this...
  2. Destination Russia for new NYK Logistics warehouse Logistics specialist NYK is expanding its market presence with the launch of new warehousing operation in Moscow, Russia.
  3. Pfizer agrees sale of consumer healthcare business to J&J Pfizer Inc has reached an agreement to sell its consumer healthcare business to Johnson & Johnson (J&J) for US$16.6bn (euro13.2bn) in cash.
  4. Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with...
  5. AstraZeneca's tozorakimab meets primary endpoint in both Phase III COPD trials AstraZeneca has reported positive results from the OBERON and TITANIA Phase III trials, with tozorakimab significantly reducing moderate-to-severe COPD exacerbations compared...

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

Related Content

You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Pharmaceutical

Novo Nordisk and Hims end GLP-1 spat, strike deal to sell Wegovy and Ozempic

The pair have reached an agreement under which the telehealth company can sell Novo's Ozempic and Wegovy, ending a legal dispute that flared last month
Manufacturing

Novo Nordisk plans Ireland expansion to manufacture oral Wegovy for global markets

The company is preparing to scale production capacity at its Athlone facility as strong US uptake of its oral obesity therapy supports a broader strategy to expand global supply and compete in the fast-growing GLP-1 market
Regulatory

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Finance

Global consortium launches to accelerate antibiotic discovery

The $60m consortium backed by the Gates Foundation, Novo Nordisk Foundation and Wellcome aims to speed the discovery of next-generation antibiotics to tackle the growing threat of antimicrobial resistance
Finance

Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation

The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation
Subscribe now